Specificity of using botulinic toxin type A for blepharospasm treatment

Blepharospasm (BS) is one of the diseases characterized exclusively by involuntary face movements (facial hyperkinesis). Typical clinical manifestations include squinting or increased blinking. Among frequent patients’ complains at the disease onset are unpleasant irritations, a foreign body sensation, itching, dry eyes, and frequent blinking. Dynamism is a typical BS feature: 1) it increases during emotional stress, in stressful situations, during fatigue, eye strain (reading), in bright light; 2) disappears while sleeping; 3) decreases after waking up; 4) «corrective gestures», such as touching skin of the eyelids, paraorbital regions and glabellar region, wearing glasses, chewing or absorbing sweets, other arbitrary movements, affect BS. Botulinum therapy (botulinum toxin type A (BtA) injections, in particular using Relatox, the effectiveness of which has been demonstrated in clinical studies) is considered the «gold standard» in BS treatment. BtA is injected mainly into the orbicular muscle of eye, superficially, into the upper, lower eyelids and outer eye corner. The clinical effect occurs quickly, already in the first week after injection and lasts 3 months or more. Cases of botulinum therapy inefficiency in treating BS and other facial hyperkinesis are extremely rare.

The article describes BS main clinical aspects, BtA injection schemes as well as adverse events during the therapy. Electromyography is not mandatory to assess BtA effectiveness in BS treatment, but it is necessary in cases of inefficient therapy, adverse events or the therapy complications. It is particularly important to strictly comply with recommended BtA doses, and that the drug is injected by a certified specialist only. Botulinum therapy for BS patients is a highly effective and, in most cases, the only treatment with a good safety profile.

1. Artemenko A.R., Kurenkov A.L. What do we know about botulinum toxin. Metamorfozy = Metamorphoses 2014;(5):78–87. (In Russ.).

2. Aesthetic botulinum therapy. Modern views on treating facial wrinkles with Dysport. Materials of the Consensus of the International Expert Council commented by members of the Russian Expert Council, 2010. (In Russ.). URL: http://www.botulin.ru/upload/iblock/d2b/d2bebfc314755e65d9a8596797b81a3f.pdf

3. Instruction for Relatox ® medical use. PL 001–593, 04/12/2018 (In Russ.).

4. Plotnikova E.V., Elkin V.D. Results of Relatox ® treatment for cosmetic defects of the face. Eksperimental'naya i klinicheskaya dermatokosmetologiya = Experimental and clinical dermatocosmetology 2013;6:3−6. (In Russ.).

5. Mingazova L.R., Orlova O.R. Myofascial pain syndrome: clinic, diagnosis and treatment with botulinum toxin type A (lantox® ). Effectivnaya farmakoterapiya = Effective Pharmacotherapy 2010;(15):36–43. (In Russ.).

6. Tolmacheva V.A. Cranial dystonia. Nevrologiya, nejropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics 2018;10(1):90–5. (In Russ.). DOI: 10.14412/2074-2711-2018-1-90-95.

7. Likhachev S.A., Veevnik E.V., Chernukha T.N., Korolevich E.A. Blepharospasm: from an ophthalmologist to a neurologist. Oftalmologiya. Vostochnaya Evropa = Ophthalmology. Eastern Europe 2013;(3):95–8. (In Russ.).

8. Timerbaeva S.L. Blepharospasm in search for new therapeutic options. Byulleten Natsionalnogo obshchestva po izucheniyu bolezni Parkinsona i rasstrojstv dvizheniy = Bulletin of the National Society for the Study of Parkinson’s disease and movement disorders 2013;(3):16–9. (In Russ.).

9. Orlova O.R. Blepharospasm: clinical aspects and treatment using a new Russian botulinum neuroprotein Relatox® . Metamorfozy = Metamorphoses 2017;(18):76–80. (In Russ.).

10. Orlova O.R., Konovalova Z.N., Mingazova L.N. et al. Experience of using Relatox, a new botulinum toxin type A, in clinical practice. Metamorfozy = Metamorphoses 2014;(11):2–4. (In Russ.).

11. Ingalina F.M., Trevidik P. Anatomy and botulinum toxin injections. Parizh: Meditsinskoe izdanie nauchnogo obshchestva = Paris: Medical journal of the scientific society E2e, 2012. (In Russ.).

12. The ABC of botulinum therapy. Ed. S.L. Timerbayeva. Moscow: Practical medicine, 2014. (In Russ.).

13. Beer K., Beer D. Complications of botulinum toxins use. In: Management of Complications of Cosmetic Procedures. Handling Common and More Uncommon Problems. Ed. A. Tosti, M. Pia de Padova. Moscow: MEDpress-inform, 2014. Pp.: 113–8. (In Russ.).

14. Moy R., Maas C., Monheit G., Huber M.B. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11(2):77–83. DOI:10.1001/archfacial.2009.5.

15. Klein A.W. Complication and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg 2001;20(2):109–20. DOI: 10.1053/sder.2001.25964.

16. Satardinova E.E. Ptosis as a complication of aesthetic botulinum therapy. What does a cosmetologist need to know? Metamorfozy = Metamorphoses 2016;(16):82–8. (In Russ.).

17. Chaikovskaya E. Botulinum toxin and the theory of reverse facial expression. Inekcionnye metody v kosmetologii = Injection methods in cosmetology. 2010;(1):10–6. (In Russ.).

18. Levy L.L., Emer J.J. Complications of minimally invasive cosmetic procedures: prevention and management. J Cutan Aesthet Surg 2012;5(2):121–32. DOI: 10.4103/0974-2077.99451.

19. Artemenko A.R., Mingazova L.R., Kurenkov A.L., Nekrasova-Stein L.V. Some emergency conditions in aesthetic botulinum therapy. Metamorfozy = Metamorphoses 2018;(22):62–9. (In Russ.). russiansam.ru/docs/mm22.pdf